JPRN-UMIN000011364已完成2 期
Phase II study of FOLFIRI+biweekly cetuximab for KRAS wild type unresectable colorectal cancer. - Phase II study of FOLFIRI+biweekly cetuximab.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Phase IIstudy of biweekly FOLFIRI+cetuximab treatment for unresectable KRAS-wild type colorectal cancerunresectable colorectal cancerJPRN-UMIN000011363Dept of Surgical Oncology Osaka City University Graduate School of Medicine20
已完成
2 期
Phase II study of FOLFIRI + cetuximab as induction chemotherapy followed by FOLFIRI + bevacizumab based on early tumor shrinkage in chemotherapy-naive patients with RAS wild-type colorectal cancerColorectal cancerJPRN-UMIN000023026Department of Clinical Oncology, St. Marianna University School of Medicine54
进行中（未招募）
1 期
Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / Vadvanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / VEUCTR2018-003778-29-ITIstituto Nazionale Tumori G. Pascale34
已完成
1 期
Phase I study of FOLFOXIRI+cetuximab in patients with RAS wild-type unresectable colorectal cancerRAS wild-type unresectable colorectal cancerJPRN-UMIN000015620Aichi Cancer Center Hospital12
已完成
2 期
Phase II trial of bi-weekly cetuximab plus mFOLFOX6 or cetuximab plus mFOLFIRI for unresectable advanced or recurrent KRAS wild type colorectal cancer (T-CORE1201)colorectal cancerJPRN-UMIN000008298Tohoku Clinical Oncoogy, Research and Education Society(T-CORE)66